Loading...
Olink Holding AB (publ)
OLK•NASDAQ
Healthcare
Medical - Diagnostics & Research
$26.08
$0.08(0.31%)

The company's financials show resilient growth, with revenue advancing from $29.44M in Q2 2023 to $28.59M in Q1 2024. Gross profit remained healthy with margins at 61% in Q1 2024 compared to 59% in Q2 2023. Operating income hit -$26.23M last quarter, sustaining a consistent -92% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$20.89M. Net income dropped to -$15.97M, while earnings per share reached -$0.13. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan